Related Experiment Videos

[Antibiotic sensitivity of Pasteurella multocida and related bacteria (bacterial groups M5 and EF4). Studies of

Pathologie-Biologie
|December 1, 1986
PubMed

Insights

Pasteurella multocida from animal bites show high sensitivity to beta-lactam antibiotics, quinolones, and tetracyclines. Macrolides demonstrate limited effectiveness against these bacteria.

Area of Science:

  • Bacteriology and Infectious Diseases
  • Antimicrobial Resistance
  • Public Health Microbiology

Context:

  • Resurgence of rabies in Eastern France has led to increased animal bite consultations and subsequent bacteriologic analysis.
  • Growing need to understand the antimicrobial susceptibility patterns of Pasteurella multocida and related bacteria isolated from human infections.
  • Evaluation of antibiotic efficacy is crucial for effective treatment of infections resulting from animal-related injuries.

Purpose:

  • To determine the in vitro sensitivity of Pasteurella multocida, EF4, and M5 strains to a panel of 30 antibiotics.
  • To identify antibiotics with the lowest Minimum Inhibitory Concentrations (MIC) for effective treatment of Pasteurella infections.
  • To compare the susceptibility profiles of P. multocida, EF4, and M5 strains.

Summary:

  • Agar dilution method determined MICs for 34 human-origin P. multocida strains (from bites/expectorations), 4 EF4, and 4 M5 strains.
  • Pasteurella multocida demonstrated high sensitivity to beta-lactams (ureido-penicillins, amino-benzylpenicillins, 3rd gen cephalosporins), chloramphenicol, tetracyclines, and quinolones.
  • Fosfomycin, colistin, and aminoglycosides showed activity but with higher MICs; macrolides were largely ineffective. EF4 strains showed some resistance to penicillin G and early cephalosporins.

Impact:

  • Provides critical data for guiding antibiotic selection in treating Pasteurella multocida infections, particularly those related to animal bites.
  • Highlights the effectiveness of specific antibiotic classes, aiding clinicians in empirical and targeted therapy decisions.
  • Informs antimicrobial stewardship efforts and surveillance of resistance patterns in clinically relevant bacteria.

Related Concept Videos